1.
|
6 p, 916.0 KB |
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
/
De Mattos-Arruda, Leticia (Universitat Autònoma de Barcelona) ;
Mayor, Regina (Vall d'Hebron Institut d'Oncologia) ;
Ng, Charlotte K. Y. (Memorial Sloan Kettering Cancer Center) ;
Weigelt, Britta (Memorial Sloan Kettering Cancer Center) ;
Martinez-Ricarte, Fran (Universitat Autònoma de Barcelona) ;
Torrejon, Davis (Vall d'Hebron Institut d'Oncologia) ;
Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ;
Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ;
Raventós, Carolina (Vall d'Hebron Institut d'Oncologia) ;
Tang, Jiabin (Memorial Sloan Kettering Cancer Center) ;
Guerini-Rocco, Elena (Memorial Sloan Kettering Cancer Center) ;
Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Lois, Sergio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Marín, Oscar (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
de la Cruz, Xavier (Institució Catalana de Recerca i Estudis Avançats) ;
Piscuoglio, Salvatore (Memorial Sloan Kettering Cancer Center) ;
Towers, Russel (Department of Surgery, Memorial Sloan Kettering Cancer Center) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Ramón y Cajal, Santiago (Universitat Autònoma de Barcelona) ;
Carles, Joan (Vall d'Hebron Institut d'Oncologia) ;
Rodon, Jordi (Vall d'Hebron Institut d'Oncologia) ;
González-Cao, María (Quirón Dexeus University Hospital) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Felip, Enriqueta (Universitat Autònoma de Barcelona) ;
Sahuquillo Barris, Juan (Universitat Autònoma de Barcelona) ;
Berger, Michael F. (Memorial Sloan Kettering Cancer Center) ;
Cortés, Javier (Universitat Autònoma de Barcelona) ;
Reis-Filho, Jorge S. (Memorial Sloan Kettering Cancer Center) ;
Seoane, Joan (Universitat Autònoma de Barcelona)
Cell-free circulating tumour DNA (ctDNA) in plasma has been shown to be informative of the genomic alterations present in tumours and has been used to monitor tumour progression and response to treatments. [...]
2015 - 10.1038/ncomms9839
Nature communications, Vol. 6 (november 2015)
|
|
2.
|
12 p, 5.0 MB |
Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
/
Vicario, Rocio (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ;
Zacarias-Fluck, Mariano (Vall d'Hebron Institut d'Oncologia) ;
Zhang, Junjie (Vall d'Hebron Institut d'Oncologia) ;
Martínez-Barriocanal, Águeda (Vall d'Hebron Institut d'Oncologia) ;
Navarro Jiménez, Alexandra (Hospital Universitari Vall d'Hebron) ;
Aura, Claudia (Vall d'Hebron Institut d'Oncologia) ;
Burgues, Octavio (Hospital Clínic Universitari (València)) ;
Lluch, Ana (Hospital Clínic Universitari (València)) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Rubio, Isabel T. (Vall d'Hebron Institut d'Oncologia) ;
Marangoni, Elisabetta (Institut Curie) ;
Deeds, James (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ;
Boehm, Markus (Novartis Pharma AG (Suïssa)) ;
Schlegel, Robert (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ;
Boehm, Markus (Novartis Pharma AG (Suïssa)) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Mosher, Rebecca (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ;
Boehm, Markus (Novartis Pharma (Suïssa)) ;
Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ;
Universitat Autònoma de Barcelona
A chromosomal region that includes the gene encoding HER2, a receptor tyrosine kinase (RTK), is amplified in 20% of breast cancers. Although these tumors tend to respond to drugs directed against HER2, they frequently become resistant and resume their malignant progression. [...]
2015 - 10.1371/journal.pone.0129876
PloS one, Vol. 10 (june 2015)
|
|
3.
|
8 p, 1.6 MB |
Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer : a subgroup analysis from the phase 3 TAGS study
/
Mansoor, Wasat (The Christie NHS Foundation Trust) ;
Arkenau, Hendrik-Tobias (University College London) ;
Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ;
Shitara, Kohei (National Cancer Center Hospital East) ;
Thuss-Patience, Peter (Charité-Universitätsmedizin Berlin) ;
Cuffe, Sinead (St. James's Hospital) ;
Dvorkin, Mikhail (Omsk Regional Clinical Centre of Oncology) ;
Park, David (St, Joseph Heritage Healthcare) ;
Ando, Takayuki (University of Toyama) ;
Van Den Eynde, Marc (UCL Cliniques Universitaires Saint-Luc) ;
Beretta, Giordano D. (Humanitas Gavazzeni) ;
Zaniboni, Alberto (Fondazione Poliambulanza-Istituto Ospedaliero) ;
Doi, Toshihiko (National Cancer Center Hospital East) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Ilson, David H. (Memorial Sloan Kettering Cancer Center) ;
Makris, Lukas (Stathmi, Inc, New Hope, PA USA) ;
Benhadji, Karim A. (Taiho Oncology) ;
Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Universitat Autònoma de Barcelona
Patients with advanced gastroesophageal junction cancer (GEJC) have poor survival outcomes, and GEJC-specific data from trials evaluating agents in gastric cancers (GCs) as a whole are lacking. Trifluridine/tipiracil (FTD/TPI) was approved for previously treated metastatic GC or GEJC (mGC/mGEJC) based on results of the phase 3 TAGS trial. [...]
2021 - 10.1007/s10120-021-01156-x
Gastric Cancer, Vol. 24 (march 2021) , p. 970-977
|
|
4.
|
14 p, 502.9 KB |
Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe
/
Pinato, David J. (Imperial College London. Department of Surgery & Cancer) ;
Lee, Alvin J.X. (University College London Hospitals) ;
Biello, Federica (University of Piemonte Orientale) ;
Seguí, Elia (Hospital Clínic i Provincial de Barcelona) ;
Aguilar-Company, Juan (Hospital Universitari Vall d'Hebron) ;
Carbó, Anna (Hospital Universitari de Girona Doctor Josep Trueta) ;
Bruna, Riccardo (University of Piemonte Orientale) ;
Bower, Mark (Chelsea & Westminster Hospital) ;
Rizzo, Gianpiero (Fondazione IRCCS Policlinico San Matteo) ;
Benafif, Sarah (University College London Hospitals) ;
Carmona, Carme (Hospital Universitari de Girona Doctor Josep Trueta) ;
Chopra, Neha (University College London Hospitals) ;
Cruz, Claudia Andrea (Hospital Clínic i Provincial de Barcelona) ;
D'avanzo, Francesca (University of Piemonte Orientale) ;
Evans, Joanne S. (Imperial College London) ;
Galazi, Myria (University College London Hospitals) ;
Garcia-Fructuoso, Isabel (Hospital Universitari de Girona Doctor Josep Trueta) ;
Pria, Alessia D. (Chelsea & Westminster Hospital) ;
Newsom-Davis, Thomas (Chelsea & Westminster Hospital) ;
Ottaviani, Diego (University College London Hospitals) ;
Patriarca, Andrea (University of Piemonte Orientale) ;
Reyes, Roxana (Hospital Clínic i Provincial de Barcelona) ;
Sharkey, Rachel (University of Piemonte Orientale) ;
Sng, Christopher C.T. (University College London Hospitals) ;
Wong, Yien Ning Sophia (University College London Hospitals) ;
Ferrante, Daniela (University of Piemonte Orientale) ;
Scotti, Lorenza (University of Piemonte Orientale) ;
Avanzi, Gian Carlo (University of Piemonte Orientale) ;
Bellan, Mattia (University of Piemonte Orientale) ;
Castello, Luigi Mario (University of Piemonte Orientale) ;
Marco-Hernández, Javier (Hospital Clínic i Provincial de Barcelona) ;
Mollà, Meritxell (Hospital Clínic i Provincial de Barcelona) ;
Pirisi, Mario (University of Piemonte Orientale) ;
Ruiz-Camps, Isabel (Hospital Universitari Vall d'Hebron) ;
Sainaghi, Pier Paolo (University of Piemonte Orientale) ;
Gaidano, Gianluca (University of Piemonte Orientale) ;
Brunet, Joan (Hospital Universitari de Girona Doctor Josep Trueta) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Gennari, Alessandra (University of Piemonte Orientale) ;
Universitat Autònoma de Barcelona
We describe the outcomes in cancer patients during the initial outbreak of the COVID-19 in Europe from the retrospective, multi-center observational OnCovid study. We identified 204 cancer patients from eight centers in the United Kingdom, Italy, and Spain aged > 18 (mean = 69) and diagnosed with COVID-19 between February 26th and April 1st, 2020. [...]
2020 - 10.3390/cancers12071841
Cancers, Vol. 12 Núm. 7 (july 2020) , p. 1-13
|
|
5.
|
17 p, 1.9 MB |
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT) : an international, randomised, phase 3, non-inferiority trial
/
Iveson, Timothy J (Southampton University Hospital NHS Foundation Trust, Southampton, UK) ;
Kerr, Rachel S (Department of Oncology, University of Oxford, Oxford, UK) ;
Saunders, Mark P (The Christie Hospital, Manchester, UK) ;
Cassidy, Jim (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Hollander, Niels Henrik (Westmead Hospital) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Haydon, Andrew (Australasian Gastro-Intestinal Trials Group, Melbourne, VIC, Australia) ;
Glimelius, Bengt (IGP, University of Uppsala, Uppsala, Sweden) ;
Harkin, Andrea (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Allan, Karen (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
McQueen, John (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Scudder, Claire (OCTO, University of Oxford, Department of Oncology, Oxford, UK) ;
Boyd, Kathleen Anne (Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK) ;
Briggs, Andrew (Memorial Sloan-Kettering Cancer Centre) ;
Waterston, Ashita (Beatson West of Scotland Cancer Centre (Glasgow, Regne Unit)) ;
Medley, Louise (Royal United Hospital, Bath, UK) ;
Wilson, Charles (Addenbrookes Hospital (Cambridge, Regne Unit)) ;
Ellis, Richard (Royal Cornwall Hospital NHS Trust, Truro, UK) ;
Essapen, Sharadah (St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK) ;
Dhadda, Amandeep S (Castle Hill Hospital) ;
Harrison, Mark (Mount Vernon Cancer Centre, Northwood, UK) ;
Falk, Stephen (Bristol Cancer Institute, Bristol, UK) ;
Raouf, Sherif (Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK) ;
Rees, Charlotte (Southampton University Hospital NHS Foundation Trust, Southampton, UK) ;
Olesen, Rene K (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Propper, David (Barts Cancer Institute (BCI)) ;
Bridgewater, John (UCL Cancer Institute, University College London, London UK) ;
Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK) ;
Farrugia, David (Gloucestershire Oncology Centre, Cheltenham General Hospital, Cheltenham, UK) ;
Webb, Andrew (Brighton and Sussex University Hospital Trust) ;
Cunningham, David (Royal Marsden Hospital, London, UK) ;
Hickish, Tamas (Poole Hospital, Bournemouth University, Bournemouth, UK) ;
Weaver, Andrew (Department of Oncology, Oxford University Hospitals Foundation Trust, Oxford, UK) ;
Gollins, Simon (North Wales Cancer Treatment Centre, Rhyl, UK) ;
Wasan, Harpreet S (Hammersmith Hospital, Imperial College London, London, UK) ;
Paul, James (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Universitat Autònoma de Barcelona
6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. [...]
2018 - 10.1016/S1470-2045(18)30093-7
The Lancet. Oncology, Vol. 19 (april 2018) , p. 562-578
|
|
6.
|
6 p, 754.7 KB |
Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer : a post hoc analysis of the MOSAIC trial
/
Auclin, Edouard (Bourgogne Franche-Comté University, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France) ;
André, Thierry (Oncology Multidisciplinary Research Group (GERCOR)) ;
Taieb, Julien (UMR-S 1147, INSERM) ;
Banzi, Maria (Unit of Medical Oncology, Clinical Cancer Center, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy) ;
Van Laethem, Jean-Luc (Université Libre de Bruxelles. Department of Gastroenterology and Digestive diseases, Hopital Erasme) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Hickish, Tamas (Royal Bournemouth Hospital and Bournemouth University. Department of Oncology) ;
de Gramont, Aimery (Institut Hospitalier Franco-Britannique. Department of Oncology) ;
Vernerey, Dewi (Oncology Multidisciplinary Research Group (GERCOR)) ;
Universitat Autònoma de Barcelona
Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2. 35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed post-operative CEA prognostic value for survival outcomes and predictive value for the addition of oxaliplatin to adjuvant treatment. [...]
2019 - 10.1038/s41416-019-0521-7
British Journal of Cancer, Vol. 121 (july 2019) , p. 312-317
|
|
7.
|
9 p, 1.3 MB |
Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies : exploratory analyses of the RAISE trial and validation in an electronic medical record data set
/
Grothey, Axel (Mayo Clinic) ;
Yoshino, Takayuki (National Cancer Center Hospital East) ;
Bodoky, Gyorgy (St László Hospital) ;
Ciuleanu, Tudor (The Oncology Institute Prof Dr Ion Chiricută and Iuliu Hațieganu University of Medicine and Pharmacy) ;
García-Carbonero, Rocío (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ;
Muro, Kei (Aichi Cancer Center Hospital) ;
Mytelka, Daniel S (Formerly of Eli Lilly and Company) ;
Li, Li (Eli Lilly and Company) ;
Lipkovich, Olga (Eli Lilly and Company) ;
Hsu, Yanzhi (Eli Lilly and Company) ;
Sashegyi, Andreas (Eli Lilly and Company) ;
Ferry, David (Eli Lilly and Company) ;
Nasroulah, Federico (Eli Lilly Argentina) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had a higher incidence of neutropaenia, leading to more chemotherapy dose modifications and discontinuations. [...]
2018 - 10.1136/esmoopen-2018-000347
ESMO open, Vol. 3 (april 2018)
|
|
8.
|
13 p, 6.8 MB |
Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity
/
Prat, Aleix (Vall d'Hebron Institut d'Oncologia) ;
Adamo, Barbara (Vall d'Hebron Institut d'Oncologia) ;
Fan, Cheng (Lineberger Comprehensive Cancer Center, University of North Carolina) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Vidal, Maria (Vall d'Hebron Institut d'Oncologia) ;
Galván, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Palmer, Héctor G. ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Dawood, Shaheenah (Department of Medical Oncology, Dubai Hospital) ;
Rodón, Jordi (Vall d'Hebron Institut d'Oncologia) ;
Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron) ;
Campo, Josep Maria Del (Vall d'Hebron Institut d'Oncologia) ;
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
To improve our understanding of the biological relationships among different types of cancer, we have characterized variation in gene expression patterns in a set of 1,707 samples representing 6 human cancer types (breast, ovarian, brain, colorectal, lung adenocarcinoma and squamous cell lung cancer). [...]
2013 - 10.1038/srep03544
Scientific reports (Nature Publishing Group), Vol. 3 (december 2013)
|
|
9.
|
19 p, 418.6 KB |
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer : Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
/
Van Cutsem, Eric (University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium) ;
Huijberts, Sanne (Netherlands Cancer Institute, Amsterdam, the Netherlands) ;
Grothey, Axel (West Cancer Center, Germantown, TN) ;
Yaeger, Rona (Memorial Sloan Kettering Cancer Center) ;
Cuyle, Pieter-Jan (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Fakih, Marwan (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ;
Montagut, Clara (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Peeters, Marc (University Hospital Antwerp (Bèlgica)) ;
Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ;
Wasan, Harpreet (Hammersmith Hospital, Imperial College London, London, United Kingdom) ;
Desai, Jayesh (Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia) ;
Ciardiello, Fortunato (University of Campania "Luigi Vanvitelli," Naples, Italy) ;
Gollerkeri, Ashwin (Array BioPharma Inc, Boulder, CO) ;
Christy-Bittel, Janna (Array BioPharma Inc, Boulder, CO) ;
Maharry, Kati (Array BioPharma Inc, Boulder, CO) ;
Sandor, Victor (Array BioPharma Inc, Boulder, CO) ;
Schellens, Jan H.M. (Utrecht University, Utrecht, the Netherlands) ;
Kopetz, Scott (The University of Texas MD Anderson Cancer Center, Houston, TX) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
VHIR Vall d'Hebron Institut de Recerca
To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, phase III BEACON Colorectal Cancer trial ( identifier: ; European Union Clinical Trials Register identifier: EudraCT2015-005805-35). [...]
2019 - 10.1200/JCO.18.02459
Journal of Clinical Oncology, Vol. 37 (march 2019) , p. 1460-1469
|
|
10.
|
7 p, 1.3 MB |
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
/
Melisi, Davide (University of Verona, Piazzale Ludovico Antonio Scuro) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ;
Pezet, Denis (Centre Hospitalier Universitaire) ;
Deplanque, Gael (Hôpital Riviera-Chablais) ;
Fuchs, Martin (Klinikum Bogenhausen, Städtisches Klinikum München GmbH, Englschalkinger Road 77, 81925 Munich, Germany) ;
Trojan, Jorg (Goethe University Medical Center) ;
Oettle, Helmut (Onkologische und Hämatologische Schwerpunktpraxis, Friedrichshafen, Germany) ;
Kozloff, Mark (Ingalls Memorial Hospital) ;
Cleverly, Ann (Eli Lilly and Company, Erl Wood Manor, Windlesham) ;
Smith, Claire (formerly of Eli Lilly and Company) ;
Estrem, Shawn T. (Eli Lilly and Company, Lilly Corporate Center) ;
Gueorguieva, Ivelina (Eli Lilly and Company, Erl Wood Manor, Windlesham) ;
Lahn, Michael M. F. (Wisconsin Ave., #8008, Bethesda, MD 20815 USA) ;
Blunt, Al (Advaxis, Inc) ;
Benhadji, Karim A. (Eli Lilly and Company) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Universitat Autònoma de Barcelona
Galunisertib is the first-in-class, first-in-human, oral small-molecule type I transforming growth factor-beta receptor (ALK5) serine/threonine kinase inhibitor to enter clinical development. The effect of galunisertib vs. [...]
2018 - 10.1038/s41416-018-0246-z
British Journal of Cancer, Vol. 119 (october 2018) , p. 1208-1214
|
|